Richard James  Whitley net worth and biography

Richard Whitley Biography and Net Worth

Director of Virios Therapeutics
Richard James Whitley, MD, is a Distinguished Professor of Pediatrics and a Professor of Microbiology, Medicine, and Neurosurgery at the University of Alabama at Birmingham (UAB). He is also Loeb Eminent Scholar Chair in Pediatrics; Co-Director of the Division of Pediatric Infectious Diseases; Vice-Chair of the Department of Pediatrics; Senior Scientist in the Department of Gene Therapy; Scientist at the Cancer Research and Training Center; Faculty at the Gene Therapy Center; Senior Leader of the Pediatric Oncology Program at the Comprehensive Cancer Center; Director of the UAB Center for Emerging Drug Discovery; and Co-Founder and Co-Director of the Alabama Drug Discovery Alliance.

Dr. Whitley received his medical degree from George Washington University. He then served a residency in pediatrics and
a fellowship in infectious diseases/virology at the University of Alabama at Birmingham.

Dr. Whitley is board certified by the American Board of Pediatrics, with a subspecialty in infectious diseases. He is Associate Editor of Journal of Infectious Diseases and is a member of the editorial board of many other scholarly journals, including Antimicrobial Agents and Chemotherapy, Reviews of Infectious Diseases, Human Gene Therapy, and Current Opinion in Infectious Diseases.

Dr. Whitley’s major research interests include antiviral therapies directed against medically important viral diseases of children and adults, including neonatal herpes simplex virus infection, herpes simplex encephalitis, herpes zoster, enteroviral infections of the newborn, therapeutic interventions for congenital cytomegalovirus infections, hepatitis C, and respiratory virus diseases in the immunocompromised host; and the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy of herpesvirus infections and engineering of herpes simplex virus for gene therapy. He is a past President of the Infectious Diseases Society of America (IDSA) and was the inaugural recipient of the Distinguished Clinical Research Scholar and Educator in Residence at the NIH Clinical Center. In addition, he is the author or coauthor of more than 350 published articles and 240 book chapters.

What is Richard James Whitley's net worth?

The estimated net worth of Richard James Whitley is at least $3,059.00 as of December 8th, 2022. Dr. Whitley owns 700 shares of Virios Therapeutics stock worth more than $3,059 as of November 2nd. This net worth evaluation does not reflect any other assets that Dr. Whitley may own. Learn More about Richard James Whitley's net worth.

How do I contact Richard James Whitley?

The corporate mailing address for Dr. Whitley and other Virios Therapeutics executives is , , . Virios Therapeutics can also be reached via phone at 866-620-8655 and via email at [email protected]. Learn More on Richard James Whitley's contact information.

Has Richard James Whitley been buying or selling shares of Virios Therapeutics?

Richard James Whitley has not been actively trading shares of Virios Therapeutics during the last quarter. Most recently, Richard James Whitley sold 1,800 shares of the business's stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $0.26, for a transaction totalling $468.00. Following the completion of the sale, the director now directly owns 700 shares of the company's stock, valued at $182. Learn More on Richard James Whitley's trading history.

Who are Virios Therapeutics' active insiders?

Virios Therapeutics' insider roster includes Gregory Duncan (CEO), William Pridgen (Director), and Richard Whitley (Director). Learn More on Virios Therapeutics' active insiders.

Richard James Whitley Insider Trading History at Virios Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2022Sell1,800$0.26$468.00700View SEC Filing Icon  
1/6/2022Buy1,800$5.72$10,296.00View SEC Filing Icon  
12/23/2021Buy200$5.72$1,144.00View SEC Filing Icon  
See Full Table

Richard James Whitley Buying and Selling Activity at Virios Therapeutics

This chart shows Richard James Whitley's buying and selling at Virios Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Virios Therapeutics Company Overview

Virios Therapeutics logo
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $4.37
Low: $4.28
High: $4.51

50 Day Range

MA: $1.58
Low: $0.14
High: $4.99

2 Week Range

Now: $4.37
Low: $0.13
High: $1.04

Volume

68,155 shs

Average Volume

1,049,645 shs

Market Capitalization

$84.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58